Stanford PACK-IT technology adoption signals shift toward same-day in-vivo administration.
Move expected to reduce manufacturing costs, improve patient accessibility, and expand the therapeutic market upon commercialization.
HLB Innovation has embarked on securing next-generation technology to address the high costs and complex manufacturing processes associated with existing CAR-T therapies. By shifting from patient-specific custom manufacturing to a method that generates CAR-T cells directly within the body, the company aims to reduce treatment costs and expand market reach.
On the 18th, HLB Innovation announced that its U.S. subsidiary, Verismo Therapeutics, has licensed the 'PACK-IT' platform—an in-vivo CAR-T cell generation technology—from Stanford University School of Medicine.
Under the agreement, Verismo will integrate the technology developed by the team of Professor Crystal Mackall, the founding director of the Stanford Center for Cancer Cell Therapy, into its proprietary multi-chain KIR-CAR platform to develop next-generation therapeutics.
Overcoming the Limitations of CAR-T: 3-6 Week Lead Times and Massive Costs
Conventional CAR-T therapies require harvesting a patient's T-cells, followed by genetic modification, expansion, and quality control in specialized facilities before re-infusion. This process typically takes 3 to 6 weeks, with complex logistics and high costs severely limiting patient access.
The financial burden is substantial. According to 2025 Wholesale Acquisition Cost (WAC) data in the U.S., Gilead’s Yescarta is priced at approximately $500,000, while Novartis’ Kymriah costs roughly $590,000.
Actual treatment costs are often higher. An analysis by the actuarial firm Milliman of private insurance claims from 2022 to 2025 found that the average cost per CAR-T treatment, including pre- and post-treatment medical expenses, reached approximately $810,000, with 15% of cases exceeding $1.1 million.
In South Korea, high treatment costs remain a significant burden. According to the Ministry of Health and Welfare, the cost of Kymriah reached approximately 400 million KRW per patient before health insurance coverage was applied in 2022. While insurance benefits have significantly reduced out-of-pocket expenses for eligible patients, the fiscal strain on the national health insurance system remains a challenge.
The PACK-IT platform acquired by Verismo aims to transform this manufacturing structure. It utilizes T-cell-targeting lentiviral particles to deliver CAR genes directly into the patient's body, inducing the generation of CAR-T cells in vivo.
Preclinical data has already demonstrated technical feasibility. At the 2025 American Association for Cancer Research (AACR) meeting, the Stanford research team reported that PACK-IT-based CAR-T cells exhibited superior anti-tumor activity compared to traditional lentiviral methods and confirmed leukemia suppression in animal models.
Verismo plans to combine this with its KIR-CAR platform to replace weeks-long ex-vivo manufacturing processes with a same-day in-vivo delivery method.
Developing 'Off-the-Shelf' CAR-T to Drive Market Expansion
The core significance of this technology acquisition lies in its potential to fundamentally alter the supply chain of CAR-T therapies.
While traditional CAR-T requires individual manufacturing for every patient, the in-vivo approach uses standardized gene delivery agents, allowing for mass production and in-body cell generation. Successful commercialization would eliminate the time and costs associated with cell harvesting, manufacturing, and transport, while enabling mass supply to overcome current production capacity constraints.
By alleviating wait times and price pressures, the technology could expand treatment opportunities to patients who previously faced barriers to timely care. Analysts suggest that this could broaden the growth foundation of the CAR-T market by increasing the number of treatment centers and expanding indications.
Global pharmaceutical companies are also competing to secure in-vivo CAR-T technologies. AbbVie acquired Capstan Therapeutics for $2.1 billion in 2025, and AstraZeneca acquired EsoBioTech in a deal worth up to $1 billion. These transactions underscore the growing interest in direct in-vivo generation as the next frontier in cell therapy.
Bryan Kim, CEO of Verismo, stated, "Through the adoption of the PACK-IT technology, we will expand our development scope to in-vivo CAR-T therapies and strive to provide faster, more economical treatment opportunities to more patients."







